Data from a Mayo Clinic study show, despite some reports of discomfort and dissatisfaction, a majority of patients receiving penile prosthesis are satisfied 1 year in.

"There are actually no data to support that 1 neuromodulation is better than another based on disease severity, and this is based on the systematic review done for the OAB guideline," says Anne ...

"Physician scored GU toxicity grade 2 or greater at 2 years was 51% with the CT-guided and 27% with the MRI-guided," says Amar U. Kishan, MD. In this video, Amar U. Kishan, MD, shares the initial and ...

"If a practice has determined in writing that there are insurers whose policies advised that they will not accept this code, it seems reasonable not to report that code to that insurer even when ...

"As we all know, Medicare rules do not always follow CPT directives. The same is true in this case," write Jonathan Rubenstein, MD, and Mark Painter.

Wilms tumor growth patterns differ based on the specific predisposition gene variant and its developmental timing. Around 30% of children with Wilms tumor have a mutation in a predisposition gene, ...

"As we all know, Medicare rules do not always follow CPT directives. The same is true in this case," write Jonathan Rubenstein, MD, and Mark Painter. To help answer this question, we should first ...

"It really remains to be seen whether we can expand this to care for other types of urological inpatients," says Timothy D. Lyon, MD. In this video, Timothy D. Lyon, MD, discusses the Urology Practice ...

Prostate cancer incidence and mortality are increasing, with over 313,000 diagnoses and 35,000 deaths projected for 2025. Screening practices, influenced by the US Preventive Services Task Force, have ...

"As we all know, Medicare rules do not always follow CPT directives. The same is true in this case," write Jonathan Rubenstein, MD, and Mark Painter. "From a coding standpoint and from the work ...

“The key here is I don’t believe that testosterone increases the risk of prostate cancer progression or biochemical recurrence," says Mohit Khera, MD, MBA, MPH. Overall, 39% of those who received a ...

MiR-371a-3p demonstrates high sensitivity and specificity, outperforming traditional tumor markers in testicular cancer diagnosis and monitoring. MiR-371a-3p shows potential in early relapse detection ...